Status:
COMPLETED
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
60-80 years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to investigate the safety and tolerability of AZD0328 following once-daily dosing for 13 days in elderly healthy volunteers and to define maximum tolerated dose.
Eligibility Criteria
Inclusion
- Provision of signed informed consent
- Clinically normal physical findings, laboratory values, vital signs and resting ECG as judged by the investigator
Exclusion
- History of clinically significant cardio- or cerebrovascular, pulmonary, renal, hepatic, neurological, mental or gastrointestinal disorder or any other major disorder
- History of severe allergy/hypersensitivity or symptoms/signs of ongoing allergy/hypersensitivity
- Intake of any prescribed medicine or St John's Wort, except for occasional paracetamol and nasal anticongestant, within 3 weeks or use of over-the-counter drugs within 2 weeks before the first administration of study drug
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT00687141
Start Date
November 1 2007
End Date
June 1 2008
Last Update
December 10 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Linköping, Sweden
2
Research Site
Luleå, Sweden
3
Research Site
Stockholm, Sweden
4
Research Site
Uppsala, Sweden